23andMe seeks new bids after $305 million offer from its co-founder

23andMe is seeking to reopen bidding on its assets, including its customer genetic data, after receiving a $305 million offer from co-founder Anne Wojcicki's TTAM Research Institute, exceeding Regeneron Pharmaceuticals' prior $256 million lead bid. Regeneron, while still interested, is requesting a $10 million breakup fee should Wojcicki's bid prevail, citing unfairness in reopening the auction process following 23andMe's bankruptcy filing in March after a data breach and declining consumer demand. The sale of 23andMe's assets, including over 15 million customer DNA profiles, has raised concerns among U.S. lawmakers regarding potential misuse of sensitive genetic data.

Analysis

Bankrupt genetic testing company 23andMe (MEHCQ.PK) is seeking court approval to reopen bidding for its assets, including its extensive database of customer genetic data, following a new $305 million offer from TTAM Research Institute, an entity founded by 23andMe's co-founder Anne Wojcicki. This offer significantly exceeds the previously accepted $256 million lead bid from Regeneron Pharmaceuticals (REGN.O) made during the May bankruptcy auction. Regeneron, while still expressing interest in acquiring 23andMe's assets, is now requesting a $10 million breakup fee if Wojcicki’s higher bid is ultimately accepted, arguing the initial auction was definitive. 23andMe's March bankruptcy filing was precipitated by declining consumer demand and a critical 2023 data breach that compromised the sensitive genetic and personal information of millions of customers. The sale, which includes over 15 million customer DNA profiles, has drawn considerable concern from U.S. lawmakers regarding the potential for misuse of this highly sensitive data. Notably, TTAM's initial backup bid was valued at $146 million, highlighting a substantial increase in its current offer. While the overall sentiment surrounding this development is mildly positive (sentiment score 0.3), likely reflecting the prospect of enhanced recovery for creditors due to the higher bid, 23andMe's specific ticker sentiment (MEHCQ.PK) remains deeply negative (-0.8), consistent with its bankrupt status. The market impact score of 0.25 suggests this specific development is not anticipated to cause significant broader market reverberations.

Key Decisions for Investors

• Investors in 23andMe (MEHCQ.PK) should understand that while the $305 million offer improves potential recovery for creditors, equity holders typically face a high probability of complete loss in bankruptcy proceedings.
• For those monitoring Regeneron Pharmaceuticals (REGN.O), the situation presents a contested acquisition opportunity for valuable genetic data; the key considerations are whether Regeneron will increase its bid or if the potential $10 million breakup fee impacts their valuation of the assets.
• The intense scrutiny over the sale of 15 million DNA profiles highlights increasing regulatory and ethical risks in the genetic data sector; investors with exposure to companies handling large volumes of sensitive personal or genetic data should monitor for heightened compliance burdens and reputational risks.
• Given 23andMe's (MEHCQ.PK) bankruptcy status and the inherent volatility, any speculative trading in its stock carries exceptionally high risk and is generally unsuitable for most investment strategies.